JP2021518431A5 - - Google Patents

Info

Publication number
JP2021518431A5
JP2021518431A5 JP2020573085A JP2020573085A JP2021518431A5 JP 2021518431 A5 JP2021518431 A5 JP 2021518431A5 JP 2020573085 A JP2020573085 A JP 2020573085A JP 2020573085 A JP2020573085 A JP 2020573085A JP 2021518431 A5 JP2021518431 A5 JP 2021518431A5
Authority
JP
Japan
Prior art keywords
constipation
dgat1
pharmaceutical composition
inhibitor
pyridine
Prior art date
Application number
JP2020573085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518431A (ja
JPWO2019178492A5 (https=
JP7527984B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022499 external-priority patent/WO2019178492A1/en
Publication of JP2021518431A publication Critical patent/JP2021518431A/ja
Publication of JPWO2019178492A5 publication Critical patent/JPWO2019178492A5/ja
Publication of JP2021518431A5 publication Critical patent/JP2021518431A5/ja
Application granted granted Critical
Publication of JP7527984B2 publication Critical patent/JP7527984B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573085A 2018-03-16 2019-03-15 重度の便秘を治療するための組成物及び方法 Active JP7527984B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
US62/644,033 2018-03-16
PCT/US2019/022499 WO2019178492A1 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Publications (4)

Publication Number Publication Date
JP2021518431A JP2021518431A (ja) 2021-08-02
JPWO2019178492A5 JPWO2019178492A5 (https=) 2022-02-21
JP2021518431A5 true JP2021518431A5 (https=) 2022-02-21
JP7527984B2 JP7527984B2 (ja) 2024-08-05

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573085A Active JP7527984B2 (ja) 2018-03-16 2019-03-15 重度の便秘を治療するための組成物及び方法

Country Status (17)

Country Link
US (4) US11224590B2 (https=)
EP (1) EP3765012B1 (https=)
JP (1) JP7527984B2 (https=)
KR (1) KR102747096B1 (https=)
CN (1) CN111936137B (https=)
AU (1) AU2019234956B2 (https=)
BR (1) BR112020018790A2 (https=)
EA (1) EA202092190A1 (https=)
FI (1) FI3765012T3 (https=)
IL (1) IL277332B2 (https=)
MX (1) MX2020009604A (https=)
MY (1) MY205335A (https=)
PE (1) PE20210158A1 (https=)
PH (1) PH12020551468A1 (https=)
SG (1) SG11202008971VA (https=)
TW (1) TWI704917B (https=)
WO (1) WO2019178492A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL277332B2 (en) 2018-03-16 2025-01-01 Anji Pharmaceuticals Inc Preparations and methods for treating severe constipation
KR20220052459A (ko) 2020-10-21 2022-04-28 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
WO1999067268A1 (en) 1998-06-24 1999-12-29 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
JP2004502686A (ja) 2000-06-30 2004-01-29 スージェン・インコーポレーテッド 4−ヘテロアリール−3−ヘテロアリーリデニル−2−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Dgat阻害剤
KR100772297B1 (ko) 2002-11-22 2007-11-02 니뽄 다바코 산교 가부시키가이샤 융합 비시클릭 질소-함유 헤테로사이클
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
EP1653969A4 (en) 2003-08-07 2006-12-20 Japan Tobacco Inc PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
EP1718309A2 (en) 2004-01-30 2006-11-08 Japan Tobacco, Inc. Anorectic compounds
WO2006004200A1 (ja) 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
JP2008516978A (ja) 2004-10-15 2008-05-22 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満症の処置のためのビフェニル−4−イル−カルボニルアミノ酸誘導体の製造および使用
US7795283B2 (en) 2004-12-14 2010-09-14 Astrazeneca Ab Oxadiazole derivative as DGAT inhibitors
KR20080000652A (ko) 2005-04-19 2008-01-02 바이엘 파마슈티칼스 코포레이션 아릴 알킬산 유도체 및 그의 용도
WO2007002740A2 (en) 2005-06-28 2007-01-04 E. I. Du Pont De Nemours And Company Buffer compositions
EP2402320A1 (en) * 2006-03-31 2012-01-04 Novartis AG Anorectic agents
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
WO2009126624A1 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
MA34097B1 (fr) * 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
WO2011126967A1 (en) * 2010-04-08 2011-10-13 Medicinova, Inc. Methods and compositions for the treatment of irritable bowel syndrome
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013130370A2 (en) * 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
CN104936581A (zh) * 2012-08-29 2015-09-23 萨利克斯药品有限公司 用于治疗便秘和相关胃肠道疾病和疾病状态的泻药组合物和方法
US9895423B2 (en) * 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
IL277332B2 (en) 2018-03-16 2025-01-01 Anji Pharmaceuticals Inc Preparations and methods for treating severe constipation

Similar Documents

Publication Publication Date Title
Pandit et al. Current updates on oxazolidinone and its significance
JP5266430B2 (ja) 金属酵素阻害化合物
US20060106039A1 (en) Combinations
JP5786034B2 (ja) 脂質異常症の治療に適したヘテロ環式化合物
WO2003028730A2 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
JP2007016035A5 (https=)
JP2017505293A5 (https=)
JP7098214B2 (ja) 非アルコール性脂肪性肝炎(NASH)の処置のためのsGC刺激物質の使用
JP2016516020A5 (https=)
TW200827344A (en) Administration of dipeptidyl peptidase inhibitors
JP2013521286A5 (https=)
JP2010519216A (ja) Ccr5拮抗薬のための医薬組成物および方法
NZ594493A (en) Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors
JP2005517006A5 (https=)
JP2010505906A5 (https=)
JP2009515887A5 (https=)
JP2021518431A5 (https=)
JP2010516701A5 (https=)
ES2274234T3 (es) 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3(4-piridin-3-il)pirimidin -2-ilamino)fenil)-benzamida para el tratamiento de enfermedades mediadas por ang ii.
AU2006241219A1 (en) Methods of treating atherosclerosis
JP2016514141A5 (https=)
US20070299047A1 (en) Combination of Organic Compounds
AU2006311723A1 (en) Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent
NZ590315A (en) Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
JPWO2019178492A5 (https=)